Short Interest in Compass Therapeutics, Inc. (NASDAQ:CMPX) Grows By 8.3%

Compass Therapeutics, Inc. (NASDAQ:CMPX) saw a large growth in short interest in the month of September. As of September 30th, there was short interest totalling 2,490,000 shares, a growth of 8.3% from the September 15th total of 2,300,000 shares. Based on an average daily trading volume, of 423,800 shares, the short-interest ratio is presently 5.9 days. Approximately 2.9% of the company’s shares are short sold.

Institutional Trading of Compass Therapeutics

A number of hedge funds have recently made changes to their positions in the company. Opaleye Management Inc. purchased a new position in shares of Compass Therapeutics in the first quarter valued at $6,277,000. CM Management LLC boosted its position in Compass Therapeutics by 148.0% in the 1st quarter. CM Management LLC now owns 310,000 shares of the company’s stock valued at $614,000 after buying an additional 185,000 shares during the last quarter. Ground Swell Capital LLC acquired a new stake in shares of Compass Therapeutics during the second quarter valued at about $124,000. Vanguard Group Inc. increased its position in shares of Compass Therapeutics by 1.7% during the first quarter. Vanguard Group Inc. now owns 4,152,197 shares of the company’s stock worth $8,221,000 after acquiring an additional 71,008 shares during the last quarter. Finally, Renaissance Technologies LLC lifted its stake in shares of Compass Therapeutics by 99.7% in the second quarter. Renaissance Technologies LLC now owns 140,600 shares of the company’s stock worth $141,000 after acquiring an additional 70,200 shares in the last quarter. Hedge funds and other institutional investors own 68.43% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of research firms have issued reports on CMPX. Wedbush reissued an “outperform” rating and set a $8.00 price target on shares of Compass Therapeutics in a research report on Wednesday, August 7th. LADENBURG THALM/SH SH upgraded Compass Therapeutics from a “neutral” rating to a “buy” rating and set a $5.00 target price for the company in a report on Monday, September 16th. Finally, HC Wainwright reaffirmed a “buy” rating and set a $10.00 price target on shares of Compass Therapeutics in a research report on Monday, August 12th.

Compass Therapeutics Price Performance

NASDAQ CMPX traded down $0.07 during trading hours on Thursday, hitting $1.91. The company had a trading volume of 2,218,530 shares, compared to its average volume of 432,007. The firm’s 50 day moving average is $1.57 and its 200 day moving average is $1.40. Compass Therapeutics has a fifty-two week low of $0.77 and a fifty-two week high of $2.34. The company has a market capitalization of $262.11 million, a price-to-earnings ratio of -5.29 and a beta of 0.90.

Compass Therapeutics (NASDAQ:CMPX) last posted its earnings results on Monday, August 12th. The company reported ($0.10) earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of ($0.10). The company had revenue of $0.85 million during the quarter. On average, equities analysts anticipate that Compass Therapeutics will post -0.42 EPS for the current year.

About Compass Therapeutics

Compass Therapeutics, Inc, a clinical-stage oncology-focused biopharmaceutical company, engages in developing antibody-based therapeutics to treat various human diseases in the United States. The company's lead product candidates include CTX-009, a bispecific antibody that blocks Delta-like ligand 4 a ligand of Notch-1, and vascular endothelial growth factor A signaling pathways, which are critical to angiogenesis and tumor vascularization; and CTX-471, an IgG4 monoclonal antibody that is an agonist of CD137, a key co-stimulatory receptor on immune cells.